Z

Zenas BioPharma, Inc. Common Stock

ZBIONASDAQHEALTHCARE
$17.39+0.07 (+0.40%)
Market closedPrev close $17.32

Price action

Daily adjusted bars

1signal overlaid
Prior signal1

Snapshot

Key stats

AV May 29
Market cap
$1.17B
P/E ratio
--
Forward P/E
--
Beta
--
52W range
$8.91 - $44.60
Dividend yield
--
Volume
4.29M
Sector
HEALTHCARE

Analyst

Consensus price target

Live

Current

$17.39

Target

$42.12

+24.73 (+142.2%) upside12mo horizon

AlphaYou verdict

Insider Buy

LONGLive
17/ 100
WeakScore 17 / 100Issued May 19, 2026

C-suite insider bought $1.0M of ZBIO this 14d.

  • Smart money11.0/40
  • Fundamentals3.0/35
  • Technicals1.0/15
  • Macro2.0/10

Receipts

Recent signals for this ticker

  • LONGMay 19
    Insider Buy

    C-suite insider bought $1.0M of ZBIO this 14d.

    Public Recommendation·Checkpoints pending

Smart money

Insider, fund, and political flow

Live5 receipts
  • insider buy

    Chief Executive Officer MOULDER LEON O JR bought $1.0M

    +3038400.0
  • filing 13f fund flow

    Two Sigma Investments LP holds $5.4M (13F 2026-03-31)

    +4.0
  • filing 13f fund flow

    Citadel Advisors LLC holds $888K (13F 2025-12-31)

    +4.0
  • filing 13f fund flow

    FMR LLC (Fidelity) holds $279.7M (13F 2025-12-31)

    +3.0
  • short interest change

    short-volume tape softening: latest 58.9% fell 6.6pp vs 20d avg 65.5%

    +1.0

Top trader activity

Pending

Copy-trading signal layer from real US-equity operators. Wires in once the CopyTrading feed is mapped to US-stock tickers.

BTC Astro risk regime

Pending

Cross-asset risk timing overlay. Used as context only, never a primary stock source.

Reputation

Sources and actors behind this ticker

Source families

Actors and filers

Checkpoint ledger

Public recommendation outcomes

Pending

No public recommendation checkpoints have landed for this ticker yet.

D7 appears first, then D15 and D30 as the call matures.

Each row is a public recommendation. Alpha columns compare the frozen issued price with SPY, QQQ, and sector ETF checkpoints when available.

Raw source coverage

Primary-source receipt chain

100.0%
Linked
1
Events
1
Signals
1
Recs
Source coverage1/1
SEC EDGAR Form 41/1 linked
Recent source events
  • SEC EDGAR Form 4

    INSIDER BUY · May 19· source

    raw linked

Fundamentals

Valuation, quality, growth

Live

Valuation

  • P/E--
  • Forward P/E--
  • P/S119.50
  • P/B3.49

Quality

  • Profit margin0.0%
  • Operating margin0.0%
  • ROE-137.1%
  • ROA-29.1%

Growth

  • Revenue YoY--
  • Earnings YoY--
  • Beta--
  • Dividend yield--

Technicals

Trend, momentum, levels

Live

Trailing returns

  • 5d+1.10%
  • 20d-0.11%
  • 60d-0.69%

Trend vs SMAs

  • vs SMA50+0.64%
  • vs SMA200-0.21%

52w range position

$8.9124%$44.60

Computed from AV daily adjusted bars. No options-flow, IV, or order-book signals on this page yet.

Macro

Sector + regime context

Live
  • macro regime shift

    VIX 18.4 (mild) as of 2026-05-15

    +18.4
  • macro regime shift

    10y-2y spread 50bps (flattish) as of 2026-05-15

    +0.5
  • macro regime shift

    Industrial Production 102.5 (mild expansion) as of 2026-04-01

    +102.5
  • macro regime shift

    Initial claims 211,000 vs 26w mean (ratio 0.99, neutral)

    +1.0
  • macro regime shift

    CPI YoY 3.95% (hot vs Fed target)

    +4.0

Earnings

EPS beat / miss history

Pending

No stored earnings history for this ticker.

The AV EARNINGS sweep backfills 8+ quarters per coverage cycle.

Debate

Key issues

Live
  • Bullish view

    • Chief Executive Officer MOULDER LEON O JR bought $1.0M
    • Two Sigma Investments LP holds $5.4M (13F 2026-03-31)
    • Citadel Advisors LLC holds $888K (13F 2025-12-31)
    • FMR LLC (Fidelity) holds $279.7M (13F 2025-12-31)

    Bearish view

    No receipts on this side yet.

Arguments are pulled from contributing receipts (Form 4 / 13F / fundamentals / macro) for this ticker. Each side carries the count of receipts behind it, not an analyst headline count.

Track record

Recommendation receipts

vs SPY

S&P 500

1 rec · 1L · 0S

Median alpha

+8.47%

Mean alpha

+8.47%

Hit rate

100.0%

Mean return

+10.76%

vs QQQ

Nasdaq-100

1 rec · 1L · 0S

Median alpha

+6.66%

Mean alpha

+6.66%

Hit rate

100.0%

Mean return

+10.76%

D7 recommendation-counted alpha. Each receipt aggregates same-day same-direction signals into one row to avoid double-counting.